NUC 1031

Drug Profile

NUC 1031

Alternative Names: Acelarin®; CPF-31; Gemzar ProTide - NuCana; MTL-007; NUC-1031

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Biliary cancer; Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 19 Jan 2018 Interim efficacy and adverse events data from a phase Ib trial in Biliary tract cancer presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GCS-2018)
  • 19 Jan 2018 NuCana plans to initiate a phase III trial for Biliary tract cancer (Late-stage disease, Combination therapy) in 2018
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Recurrent) in United Kingdom (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top